In vitro susceptibility testing in fungi: a global perspective on a variety of methods
- 1 January 2010
- Vol. 53 (1) , 1-11
- https://doi.org/10.1111/j.1439-0507.2009.01813.x
Abstract
Candida and Aspergillus species are the most common causes of invasive fungal infections in immunocompromised patients. The introduction of new antifungal agents and recent reports of resistance emerging during treatment have highlighted the need for in vitro susceptibility testing. For some drugs, there is a supporting in vitro-in vivo correlation available from studies of clinical efficacy. Both intrinsic and emergent antifungal drug resistance are encountered. Various testing procedures have been proposed, including macrodilution and microdilution, agar diffusion, disk diffusion and Etest. Early recognition of infections caused by pathogens that are resistant to one or more antifungals is highly warranted to optimise treatment and patient outcome.Keywords
This publication has 91 references indexed in Scilit:
- Triazole-resistant candidaemia following posaconazole exposureInternational Journal of Antimicrobial Agents, 2009
- Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance RegistryClinical Infectious Diseases, 2009
- First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantationDiagnostic Microbiology and Infectious Disease, 2008
- Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance MechanismPLoS Medicine, 2008
- Issues in antifungal susceptibility testingJournal of Antimicrobial Chemotherapy, 2008
- Resistance to Antifungal Agents: Mechanisms and Clinical ImpactClinical Infectious Diseases, 2008
- Multidrug Resistance in FungiEukaryotic Cell, 2007
- Multi-azole resistance in Aspergillus fumigatusInternational Journal of Antimicrobial Agents, 2006
- Advances and challenges in management of invasive mycosesThe Lancet, 2005
- In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin BAntimicrobial Agents and Chemotherapy, 2000